Health-Related Quality of Life Outcomes from Botulinum Toxin Treatment in Spasticity

Toxins (Basel). 2020 May 4;12(5):292. doi: 10.3390/toxins12050292.

Abstract

Objective: The effects of botulinum toxin injections (BoNT) on health-related quality of life along the complex spectrum of spasticity needs further characterization to guide practitioners in a real-life therapeutic environment.

Methods: In this study, we analyzed 50 consecutive and unselected patients with spasticity before and four weeks after re-injection of botulinum toxin. Health-related quality of life in terms of the EuroQol (EQ) as well as further motor and non-motor characteristics were assessed.

Results: BoNT improved the EQ visual analog scale (EQ VAS). In addition, state of health and pain maxima improved. The EQ VAS improvement correlated with pre-injection characteristics of the EQ VAS and life satisfaction in the "movement disorders" domain.

Conclusion: EQ VAS is sensitive for monitoring HR-QoL outcomes in an unselected real life observational cohort. This study may inform future studies intended to validate prediction variables that could inform on HR-QoL effects of BoNT treatment in spasticity.

Keywords: botulinum toxin; dystonia; paresis; quality of life; spasticity.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine Release Inhibitors / adverse effects
  • Acetylcholine Release Inhibitors / therapeutic use*
  • Adult
  • Aged
  • Botulinum Toxins / adverse effects
  • Botulinum Toxins / therapeutic use*
  • Female
  • Health Status
  • Humans
  • Male
  • Middle Aged
  • Muscle Spasticity / diagnosis
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / physiopathology
  • Patient Satisfaction
  • Prospective Studies
  • Quality of Life*
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome

Substances

  • Acetylcholine Release Inhibitors
  • Botulinum Toxins